preterm

SSR126768A is a novel and selective, orally active and potent oxytocin (OT) receptor antagonist with inhibitory effects on uterine contractions for the prevention of preterm labor.

Erlosiban, also known as OBE001, is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate in assisted reproductive technology (ART).

11,12-DiHETrE, a Cytochrome P450 (P450) eicosanoid and endogenous metabolite, holds potential as a single biomarker for differentiating nonalcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH) [1] [2]. Additionally, it is utilized in preterm labor research.

Methylcarbamyl PAF C-16 (Carbamyl-PAF) is a platelet-activating factor analogue with PAF agonist properties, activating inflammation in pregnancy tissues and promoting preterm birth.

PDC31 (THG113.31; ILGHXDYK) is a D-amino acid-based oligopeptide that acts as an allosteric and non-competitive inhibitor of the FP Prostaglandin Receptor, used primarily as a smooth muscle contractile agent. It effectively reduces the strength and duration of uterine contractions in vivo, offering potential for preterm labor and primary dysmenorrhea (PD) research. Additionally, PDC31 enhances the Ca2+-dependent large-conductance K+-channel in human myometrial cells [1] [2].

Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Atosiban (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Ebopiprant, also known as OBE-022, is an Oral and Selective Prostaglandin F 2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. OBE022 exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects seen with indomethacin.

L-368,899 hydrochloride is an orally available and selective nonpeptide oxytocin receptor (OXTR) antagonist for the prevention of preterm labor.L-368,899 hydrochloride prevents oxytocin-induced anti-anomalous pain and anti-nausea, and may be useful for the study of depression.

RYTVELA TFA (H-Arg-Tyr-Thr-Val-Glu-Leu-Ala-OH) is a non-competitive metabotropic interleukin-1 receptor inhibitor with anti-inflammatory activity that inhibits upregulation of inflammation and uterine activation, and may be used for the prevention of preterm labor and for fetal protection.

Lipopolysaccharides, from E. coli O128:B12 (LPS, from Escherichia coli [O128:B12]) are lipid polysaccharide endotoxins and TLR-4 activators derived from E. coli O128:B12, characterized as a smooth (S) type LPS. This compound features a typical three-part structure: O antigen, R3 core oligosaccharide, and lipid A. It activates TLR-4 in immune cells, is useful for developing neonatal brain inflammation models in animals, and may impact preterm birth in neonates.